Main Article Content
Herman A. Neurobiological insights into infantile autism. In: The Harvard brain. Spring; 1996. p. 19-25. Available at: http://www.hcs.harvard.edu/~husn/BRAIN/vol3/contents.html. Accessed April 1, 2006.
Rapin I. Autism: current concept. N Engl J Med 1997; 337: 97-104.
Perry P, Kuperman S. Pediatric psychopharmacology: autism, clinical psychopharmacology Seminar. University of Iowa ; 2003.
Guyatt GH, Sackett DL, Cook DJ. How to use an article about therapy and prevention. JAMA 1995; 27: 59-63.
Dixon RA, Munro JF, Silcocks PB. The evidence based medicine: critical appraisal for clinical problem solving. Oxford: Read Educational and Professional Publishing Ltd. Oxford; 1997.
SIGN. Level of evidence and recommendation. Scotish Intercollegiate Guideline Network, 2001. Available at: http://www.sign.ac.uk. Accessed April 7, 2006.
McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Ach Gen Psychiatry 1998; 53: 633-41.
Masi A, Cosenza A, Mucci M, De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol 2001; 16: 395-400.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Eng J Med 2002; 347: 314-1.
Research units on pediatric psychopharmacology autism network. Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361-9.
McDougle MJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005; 162: 1142-8.
Reyes M, Buitelaar J, Toren P, Augustyns I. A randomized, double blind, placebo controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorder. Am J Psychiatry 2006; 163:402-10.
Findling RL, Aman MG, Eerdekens M. Long term, open label study of risperidone in children with severe disruptive behaviors and below average IQ. Am J Psychiatry 2004; 161: 1677-84.
Aman MG, Smedt GD, Derivan A, Lyons B. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-46.
Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. New York: McGraw-Hill Companies; 2001.
Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002; 181: 271-5.
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634-41.
Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110.